Psychomotor and Anxiolytic Effects????????? of Mexazolam in Patients with Generalised Anxiety Disorder

Ferrira, Luís; Figueira, Maria Luísa; Bessa-Peixoto, Alberto; Marieiro, António; Albuquerque, Rodolfo; Paz, Cristina; Cerqueira, Ana Cláudia Rodrigues de; Damião, Pedro; Dolgner, Ana; Dingemanse, Jasper

doi:10.2165/00044011-200323040-00003

Cited by 8 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy and tolerability of mexazolam in patients (including the elderly) with disorders associated with anxiety appears to have been previously well established based on the clinical data that is available in the literature [ 24 , 26 , 31 – 33 ]. Following on from this initial evidence, a number of additional multicenter and comparative phase III/IV clinical trials have been subsequently conducted to confirm the efficacy and safety of mexazolam for this indication [ 17 , 18 , 24 , 31 – 34 , 40 – 46 ].…”

Section: Discussionmentioning

confidence: 99%

“…Finally, the study by Ferreira et al [ 24 ] showed that there was an absence of disruptive effects on psychomotor performance following the administration of clinically effective anxiolytic dosages of mexazolam. Mexazolam demonstrated a good tolerability profile in this study, which was in agreement with the absence of psychomotor and cognitive performance impairment; this in turn may lead to better compliance.…”

Section: Discussionmentioning

confidence: 99%

“…Concomitant side effects such as drowsiness, muscle relaxation, and motor ataxia are weaker than those of diazepam and cloxazolam [ 23 ]. The results of preclinical studies also showed that mexazolam appears to have a more potent antianxiety effect than cloxazolam and diazepam, while causing less muscular relaxation, sedation, and ataxia [ 23 , 24 ].…”

Section: Mexazolammentioning

confidence: 99%

“…Ferreira et al [ 24 ] conducted a multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical trial in 60 outpatients with generalized anxiety disorder (DSM-IV criteria) who received treatment with mexazolam 1 mg TID ( n = 32) or placebo ( n = 28) for 21 days (Visit 1, screening and start of placebo run-in; Visit 2, Day 0; Visit 3, Day 7; Visit 4, Day 21). The effects of mexazolam on psychomotor performance (as assessed by the LPT Battery; primary endpoint) and clinical status (HAM-A and CGI) were evaluated.…”

Section: Mexazolammentioning

confidence: 99%

“…No statistically significant differences were seen between mexazolam and placebo with regard to the LPT Battery results (CFF, RRT, MRT, and TRT) [ 24 ]. Regarding HAM-A assessment, significant improvements in total and somatic scores were seen with mexazolam versus placebo at Day 7, but not at Day 21.…”

Section: Mexazolammentioning

confidence: 99%

See 4 more Smart Citations

Mexazolam: Clinical Efficacy and Tolerability in the Treatment of Anxiety

Fernandes

Moreira

2014

Neurol Ther

View full text Add to dashboard Cite

IntroductionMexazolam is indicated for the management of anxiety with or without psychoneurotic conditions. In adult patients, the recommended daily dosage of mexazolam is 1–3 mg, administered three times daily. The objective of this article is to review the available information on the benzodiazepine (BZD) mexazolam and its clinical utility in treating patients with anxiety.MethodsThe PubMed database was searched using the keyword “mexazolam” with no date or language restrictions applied to the search. As only 11 papers were retrieved, some previously published manuscripts of interest known by the authors (not indexed on PubMed) have been added for completeness. Relevant information was selected for inclusion by the authors.ResultsA number of early studies demonstrated the ability of mexazolam to reduce anxiety symptoms with few side effects in patients with disorders associated with anxiety. Following on from this preliminary evidence, controlled studies directly comparing mexazolam with other BZDs showed that the drug is more effective than bromazepam and oxazolam, and is at least as effective as alprazolam. A larger, multicenter, phase IV study also showed that mexazolam 2 or 3 mg/day rapidly improved Hamilton Anxiety Rating Scale scores and substantially reduced the frequency and severity of numerous somatic anxiety symptoms in patients with anxiety disorders. With regard to safety, the clinical evidence indicates that mexazolam is generally well tolerated, with a low incidence of drowsiness and sedation. Furthermore, the lack of psychomotor or cognitive performance impairment following mexazolam administration may lead to better treatment compliance.ConclusionThe available clinical evidence suggests that mexazolam is an effective therapeutic option for the management of anxiety. However, larger, well-controlled clinical trials are needed to directly compare and contrast mexazolam’s efficacy and safety with other BZDs.Electronic supplementary materialThe online version of this article (doi:10.1007/s40120-014-0016-7) contains supplementary material, which is available to authorized users.

show abstract